Axsome Therapeutics to present positive phase 3 results of ACCORD─2 trial of AXS─05 in AD agitation and SYMPHONY trial ...
Axsome Therapeutics, Inc., a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, announced multiple presentations spanning its innovative, industry-leading psychiatry and neurology portfolio at the 2025 …